This website is for Healthcare Professionals only.

TEPKINLY as monotherapy is indicated for the treatment of adult patients with relapsed or refractory DLBCL after 2 or more lines of systemic therapy¹

*EPCORE™ NHL-1 trial enrolled patients with ECOG status 0-2, de novo DLBCL, DLBCL transformed from indolent lymphoma, CAR T naïve, prior CAR T, and primary refractory disease.^1,2

^†The median follow-up time was 10.7 months (range: 0.3-17.9 months) and the mean follow-up for mOS was 20 months (range: 0.3+-28.2 months).^1,3

^‡Overall survival (OS) was a secondary endpoint in the study. After a median follow-up time of 20 months (range: 0.3+-28.2 months), the mOS for patients on TEPKINLY was 19.4 months (11.7-NR).^2,3

^§Clinically meaningful improvements were reported in the Functional Assessment of Cancer Therapy-Lymphoma scores (ie, lymphoma subscale, trial outcome index, Functional Assessment of Cancer Therapy-General total score, and Functional Assessment of Cancer Therapy-Lymphoma total score) and the EuroQol-5 Dimensions-3 Levels health utility score and EuroQol visual analog scale from day 1 of cycle 1 to day 1 of cycle 9.^2,4

^||"Quick" is corroborated by the significantly faster administration with subcutaneous dosing as compared with IV alternatives.⁶

3L+=third-line plus; CI=confidence interval; CR=complete response; CRS=cytokine release syndrome; DLBCL=diffuse large B-cell lymphoma; ECOG=Eastern Cooperative Oncology Group; HRQoL=health-related quality of life; ICANS=Immune effector cell-associated neurotoxicity syndrome; IV=intravenous; mOS=median overall survival; NR=not reached; ORR=overall response rate.

TEPKINLY as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.¹

References: 1. TEPKINLY Summary of Product Characteristics. AbbVie Inc. 2. Thieblemont C, Phillips T, Ghesquieres H, et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I/II trial. J Clin Oncol. 2021;398(10306):1157-1169. doi:10.1200/JCO.22.01725 3. Jurczak W, Ghesquieres W, Karimi Y, et al. Longer follow-up from the pivotal EPCORE NHL-1 trial reaffirms subcutaneous epcoritamab induces deep, durable complete remissions in patients with relapsed/refractory large B-cell lymphoma. Hemasphere. 2023;7(suppl):e081065c. doi:10.1097/01.HS9.0000971368.08106.5c 4. Thieblemont C, Phillips T, Ghesquieres H, et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I/II trial. J Clin Oncol. (suppl). Published online December 22, 2022. doi:10.1200/JCO.22.01725 5. Hutchings M, Mous R, Clausen MR, et al. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. Lancet. 2021;398(10306):1157-1169. doi:10.1016/S0140-6736(21)00889-8 6. Stewart D, Aucoin JS, Crosbie T, et al. Update on the subcutaneous administration of rituximab in Canadian cancer centres. Curr Oncol. 2020;27(2):113-116. doi:10.3747/co.27.6041 7. Engelberts PJ, Hiemstra IH, de Jong B, et al. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. EBioMedicine. 2020;52:102625. doi:10.1016/j.ebiom.2019.102625

ALL-EPCOR-230034